Mylab Receives Approval for HPV RT-PCR Test to Detect Cervical Cancer

0

The test has high accuracy and sensitivity and is suitable for mass screening with full automation platforms

Human papillomavirus (HPV) is responsible for more than 95% of cervical cancer. Molecular tests to detect HPV play a crucial role in the prevention of cervical cancer. Continuing its commitment to introducing quality diagnostics, Pune-based start-up Mylab Discovery Solutions has launched the PathoDetect HPV Detection Test, a real-time PCR-based screening solution to detect high-intensity HPV types risk in people.

The regulatory agency-approved PathoDetect HPV Detection Test detects and differentiates the presence of high-risk HPV strains, including 16 and 18, which cause most cervical cancers.

One of the important advantages of this test is that a woman with a positive (High Risk HPV) cervical screening result may be recommended further follow-up tests at more frequent intervals. A negative test for the high-risk HPV genotypes would mean a longer interval between the next screening test.

Mylab also plans to launch an expansion of this kit that can simultaneously detect up to 15 high-risk and distinguishing features of HPV 16 and 18, covering more than 95% of cervical cancer cases.

Commenting on the launch of the PathoDetect HPV Detection Test, Hasmukh Rawal, Co-Founder and CEO of Mylab said, “Cervical cancer is preventable; Therefore, with effective screening, early diagnosis of HPV, and timely intervention by gynecologists, HPV can often be successfully treated.”

The test enables high-throughput testing that is accurate, automated, easy and reliable with Mylab Compact platform series automations within 2 hours without the need for high-end infrastructure or technical expertise.

Share.

Comments are closed.